Alkermes Plc (ALKS) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Total Assets Chart for Alkermes Plc
Alkermes Plc (ALKS) total assets for FY2025 were USD 2.5B, a 23.1% change from FY2024. Alkermes Plc's total assets grew from USD 55.7M in 1991 to USD 2.5B in 2025 (4442.6% over 34 years). Total assets compound annual growth rate: 5-year CAGR of 5.4%, 10-year CAGR of 3.1%, 20-year CAGR of 7.8%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $6.92B
- Implied Share Price
- $41.22
- Enterprise Value
- $7.98B
- Revenue (TTM)
- $1.67B
- EBITDA
- $284.93M
- Profit Margin
- 3.97%
- Trailing P/E
- 108.47
- Forward P/E
- 133.33
- Price/Book (MRQ)
- 3.91
- Price/Sales (TTM)
- 4.15
- EV/EBITDA
- 36.62
- EV/Revenue
- 4.79
- Dividend Yield
- —
- Book Value
- $10.79
- Free Cash Flow (FY2025)
- $480.33M
- Free Cash Flow Yield
- 6.95%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.